News
05-06-2013, 02:21 AM
A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab has left researchers contemplating a puzzle. The study showed a statistically non-significant benefit in clinical response rates for some patients with early breast cancer when everolimus was added to treatment with trastuzumab...
More... (http://www.medicalnewstoday.com/releases/260033.php)
More... (http://www.medicalnewstoday.com/releases/260033.php)